当前位置: 首页 > 期刊 > 《中国医学创新》 > 2012年第20期
编号:12276570
希罗达单药治疗老年晚期胃癌的临床观察(2)
http://www.100md.com 2012年7月15日 《中国医学创新》 2012年第20期
     参考文献

    [1] 秦叔逵,龚新雷.晚期胃癌化疗的现状和进展[J].临床肿瘤学杂志,2006,11 (9) :641-642.

    [2] 孙燕,石远凯.临床肿瘤学手册[M].第5版.北京:人民卫生出版社,2007:133-147.

    [3] Wagner A D,Grothe W,Haerting J,et al.Chemotherapy in advanced gastric cancer a system at ic review andmeta analysis based on aggregate data[J].J Clin Oncol,2006,24 (18):2903-2909.

    [4] Malet-Martino M,Martino R.Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine,UFT,S21):a review[J].Oncologist,2002,7(4):288-323.

    [5] Miwa M,Ura M,Nishida M, et al.Design of a novel oral xuoropyrim idine carbamate,capecitabine which generates 5-xuorouracil selectively in tumours by enzymes concen trated in human liver and cancer tissue[J].Eur J Cancer,1998, 34 (8):1274-1281.

    [6] Hong Y S,Song S Y,Lee S I,et al.A phase Ⅱ trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer[J].Ann Oncol,2004,15 (9):1344-1347.

    [7] Koizum I W. Chemotharepy for advanced gastric cancer review of global and Japanese status[J].Gastroin test Cancer Res,2007,18(5):197-203.

    (收稿日期:2012-03-30) (本文编辑:陈丹云), 百拇医药(赵晓光 宋明霞 张艳珠)
上一页1 2